Related references
Note: Only part of the references are listed.Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma
Nadja Müller et al.
JOURNAL OF IMMUNOTHERAPY (2015)
Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma
Laura A. Johnson et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells
Jianfeng Han et al.
SCIENTIFIC REPORTS (2015)
OPINION Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma
Frank B. Furnari et al.
NATURE REVIEWS CANCER (2015)
Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor
Kurt Schönfeld et al.
MOLECULAR THERAPY (2014)
EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss
John H. Sampson et al.
CLINICAL CANCER RESEARCH (2014)
A bispecific transmembrane antibody simultaneously targeting intra- and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth
Nina Mueller et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Are natural killer cells superior CAR drivers?
Hans Klingemann
ONCOIMMUNOLOGY (2014)
EGFR Phosphorylates Tumor-Derived EGFRvIll Driving STAT3/5 and Progression in Glioblastoma
Qi-Wen Fan et al.
CANCER CELL (2013)
Treatment of patients with advanced cancer with the natural killer cell line NK-92
Torsten Tonn et al.
CYTOTHERAPY (2013)
Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma
Meenakshi Hegde et al.
MOLECULAR THERAPY (2013)
Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ
Alexander Schulte et al.
NEURO-ONCOLOGY (2013)
EGFR-Targeted Granzyme B Expressed in NK Cells Enhances Natural Cytotoxicity and Mediates Specific Killing of Tumor Cells
Pranav Oberoi et al.
PLOS ONE (2013)
TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
Zakaria Grada et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2013)
Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor
Christiane Sahm et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance
T. E. Taylor et al.
CURRENT CANCER DRUG TARGETS (2012)
Radiographic patterns of relapse in glioblastoma
Marc C. Chamberlain
JOURNAL OF NEURO-ONCOLOGY (2011)
A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation
Brian Thiessen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Cetuximab Insufficiently Inhibits Glioma Cell Growth Due to Persistent EGFR Downstream Signaling
Benedikte Hasselbalch et al.
CANCER INVESTIGATION (2010)
Vaccine provides new hope for patients with deadly brain cancer
[Anonymous]
FUTURE NEUROLOGY (2010)
Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response
C. Hartmann et al.
ONCOGENE (2010)
Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
John H. Sampson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Very late relapses in glioblastoma long-term survivors
Oliver Baehr et al.
JOURNAL OF NEUROLOGY (2009)
Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
S. Arai et al.
CYTOTHERAPY (2008)
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines
Jeongwu Lee et al.
CANCER CELL (2006)
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
SQ Li et al.
CANCER CELL (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Inhibition of epidermal growth factor receptor signaling protects human malignant glioma cells from hypoxia-induced cell death
JP Steinbach et al.
CANCER RESEARCH (2004)
Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma
RO Dillman et al.
JOURNAL OF IMMUNOTHERAPY (2004)
High-level transduction and gene expression in hematopoietic repopulating cells using a human imunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter
C Demaison et al.
HUMAN GENE THERAPY (2002)
Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92
T Tonn et al.
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH (2001)
Share Paper
